DCM
SWTX

Dupont Capital Management’s SpringWorks Therapeutics SWTX Stock Holding History

Dupont Capital Management’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-5,685
Closed -$418K – 1833
2021
Q1 		$418K Sell
5,685
-1,167
-17% -$91.4K 0.01% 1021
2020
Q4 		$497K Sell
6,852
-512
-7% -$33K 0.01% 860
2020
Q3 		$351K Buy
+7,364
New +$314K 0.01% 918

Other funds holding SWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Dupont Capital Management's SWTX Position: Q2 2021 in Review

Dupont Capital Management sold out of SpringWorks Therapeutics (SWTX) in Q2 2021, closing a stake of 5,685 shares — an estimated $418K sold.

Dupont Capital Management first reported a position in SWTX in Q3 2020 and held it in 3 quarters. The position peaked at $497K in Q4 2020. 134 funds tracked by Wall St. Rank hold SWTX as of Q2 2021.

  • Dupont Capital Management reported no remaining SpringWorks Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Dupont Capital Management sold 5,685 SpringWorks Therapeutics shares in Q2 2021, an estimated $418K.
  • Dupont Capital Management first reported a position in SpringWorks Therapeutics in Q3 2020 and held it in 3 quarters.
  • Dupont Capital Management's SpringWorks Therapeutics position peaked at $497K in Q4 2020.
  • 134 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2021.

Based on Dupont Capital Management's 13F filing for Q2 2021, filed 30 Jul 2021.